As a result, we found that the upregulation of KMT2D not only correlated with a more advanced pathologic tumor grade but also contributed to aggressive cancer cell behaviors, providing a novel rationale for targeting KMT2D function in patients with OSCC. The gene discussed is KMT2D; the disease is neoplasm.